Jia-Yi H.

Investor & Advisor | Physical AI, Robotics & Life Sciences Infrastructure

📍 United Kingdom🔄 Updated September 2026💼 9 investments📅 5 years investing🗓 Last invested Dec 2025
VC🌍 United KingdomInvested this year
9
Total investments
3
Early stage
0
Mid stage
1
Late stage
5y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Independent Investor & Strategic Advisor
Dec 2025
Region VII AAA is part of the national network of Area Agencies on Aging, designed to manage and distribute and seek out funding for services for senior citizens and people with disabilities.
Independent Investor & Strategic Advisor
Nov 2025
Series A Investor / Board Observer
Feb 2023
Ascend is gene to GMP partner with deep expertise in advanced therapy development and commercialization. We offer unparalleled collaboration backed by expertise while working to develop your products from the bench through the clinic and beyond. Let’s build the future of advanced therapies together!
Board Member
2023
The MIT Club of Great Britain is a vibrant hub for alumni and friends of MIT across the United Kingdom, fostering connection, collaboration, and lifelong learning through events, networking, and community engagement.
Series A Investor
Jun 2022
Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics.
Series C Investor
Aug 2021
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
Series A Investor
Jun 2021
Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and autoimmune and inflammatory diseases, among other disorders. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis, a recently discovered and characterized cell-death mechanism. The Kojin team brings together scientific leadership in chemical biology, genetics, immunology, cancer therapeutics, drug discovery, and clinical development, as well as broad experience in biotechnology entrepreneurship.
Investor
2021
INITIATE funds and co-creates transformational companies - We focus on bold ideas at the intersection of healthcare, life sciences and technology - We are entrepreneurs and investors who have founded numerous market-defining companies - We dedicate ourselves to only a few founding teams at a time and commit to their success
Experience · 16 entries
All (16)
Investments (9)
Founder (2)
Board (2)
2026
Advisor - Healthcare Robotics
Jun 2026
Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. The nine-month program employs an objectives-based mentoring process to enhance the performance of technical founders who learn from the insights of experienced entrepreneurs, with the goal of maximizing equity-value creation. Founded by Professor Ajay Agrawal in 2012 at the University of Toronto’s Rotman School of Management, the program has expanded and now has 11 sites across six countries: Toronto, Vancouver, Calgary, Montreal, Halifax, Paris, Madison, Seattle, Estonia, Berlin, and Melbourne. The program combines 5 elements to help companies transition from science projects to scalable and financeable companies: - An emphasis on objective-setting, helping companies focus on what’s most important to their business - Focused mentorship from experienced entrepreneurs who have founded, led, and sold significant tech companies - Technical advice from world-leading scientists, engineers, and economists - Hands-on support from top business students, who embed within the company to provide business support - Opportunities to raise capital, including angels and VCs from Europe and North America The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over CAD $35 billion in equity value.
2025
Portfolio Career
Independent Investor & Strategic Advisor
Dec 2025
Independent Investor & Strategic Advisor
Dec 2025
Region VII AAA is part of the national network of Area Agencies on Aging, designed to manage and distribute and seek out funding for services for senior citizens and people with disabilities.
Independent Investor & Strategic Advisor
Nov 2025
Science & Technology Venture Fellow
Sep 2025
We create and lead a community of outstanding experts and innovators to engineer better lives.
Show all 16 entries ↓
Investment activity
2021–2025 · 9 investments
20213202212023220253
Recent (last 2 years)Earlier